©️ IP & Copyright

CAFC Draws Line: First-Filed Patents Dodge ODP Bullet in Allergan-Sun Clash

Allergan's core patent on IBS-D drug eluxadoline just got a lifeline from the CAFC. In a sharp pivot from Cellect, the court says first-filed, first-issued claims with PTA can't be knocked out by later kids in the family.

Gavel striking on stack of patent documents with CAFC seal

⚡ Key Takeaways

  • CAFC rules first-filed, first-issued patents with PTA immune to ODP from later-filed family claims. 𝕏
  • Distinguishes Cellect and Gilead, focusing on filing/issuance order. 𝕏
  • Reverses Delaware on §112 written description for Allergan continuations. 𝕏
Published by

theAIcatchup

Where law meets technology.

Worth sharing?

Get the best Legal Tech stories of the week in your inbox — no noise, no spam.

Originally reported by IPWatchdog

Stay in the loop

The week's most important stories from theAIcatchup, delivered once a week.